Humanigen up on UK nod for accelerated rolling review of COVID-19 therapy

Humanigen

09/07/2021 11:57

** Drug developer's shares  HGEN.O  up ~7% at $17.84
premarket
    ** UK's Medicines and Healthcare Products Regulatory Agency
accepts co's application seeking authorization for its drug,
lenzilumab, to treat patients hospitalized with COVID-19 (https://refini.tv/3jXqXoz)
    ** Submission has been selected for expedited COVID-related
rolling review, with assessment expected to occur more rapidly
than a standard rolling review - HGEN
    ** Rolling reviews speed up approval process by allowing
researchers to submit their findings in real-time, even before
final trial data is ready
    ** In May, HGEN submitted emergency use authorization
application to U.S. FDA for lenzilumab  urn:newsml:reuters.com:*:nL3N2NF38I
    ** As of last close, stock was down ~5% this year 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com))